News Australia starts probe into AI infiltration of Medicare The infiltration of Australia's Medicare by an AI agent raises serious questions about patient privacy and the security of confidential pharma data.
Oncology Australia, CAR-T therapy, and solid tumours Bev Menner, chief executive officer at Cell Therapies Pty Ltd, discusses CAR-T therapies for solid tumours and Australian and APAC R&D more generally.
Digital Australia, AI, and Autolomous pharmaphorum spoke with Alexander Seyf, CEO of Autolomous, about the future of AI in Australian biotech.
Market Access Approval designed from day one: Building global-ready regula... The global pharmaceutical landscape is increasingly defined by the necessity for clinical acceleration without compromising data integrity.
News Australia stands firm on 'no' to Alzheimer's drug Leqembi Eisai and Biogen have been unable to persuade Australia's medicines regulator to approve their Alzheimer's therapy Leqembi with a narrower label.
News Australia joins EU in turning down Alzheimer's drug Leqembi Australia's Therapeutic Goods Administration (TGA) has said it won't approve Eisai and Biogen's Alzheimer's disease therapy Leqembi, saying its efficacy does not outweigh its risks.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.